$PGEN
PRECIGEN, INC. Stock $pgen

$pgen Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000135609024000007 Filed on March 19, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.065M	$1.228M	$6.225M
YoY Change	-42.46%	-30.35%	-76.87%
Cost Of Revenue	$1.075M	$1.358M	$6.119M
YoY Change	-29.6%	8.04%	-3.47%
Gross Profit	-$10.00K	-$130.0K	$106.0K
YoY Change	-103.09%	-125.69%	-99.48%
Gross Profit Margin	-0.94%	-10.59%	1.7%
Selling, General & Admin	$10.15M	$10.27M	$40.42M
YoY Change	-12.78%	-10.82%	-15.81%
% of Gross Profit			38127.36%
Research & Development	$14.25M	$12.99M	$48.61M
YoY Change	17.15%	20.39%	3.06%
% of Gross Profit			45862.26%
Depreciation & Amortization	$1.595M	$1.618M	$6.668M
YoY Change	-6.78%	-5.98%	-38.06%
% of Gross Profit			6290.57%
Operating Expenses	$24.40M	$23.26M	$89.03M
YoY Change	2.51%	4.29%	-6.46%
Operating Profit	-$24.41M	-$23.39M	-$88.92M
YoY Change	3.97%	7.3%	19.19%
Interest Expense	$606.0K	$914.0K	$2.769M
YoY Change	96.12%	-244.16%	-147.91%
% of Operating Profit
Other Income/Expense, Net	$37.00K	-$77.00K	$567.0K
YoY Change	-88.65%	-129.28%	-63.16%
Pretax Income	-$23.77M	-$33.39M	-$96.36M
YoY Change	4.29%	50.61%	20.5%
Income Tax	-$29.00K	-$332.0K	-$458.0K
% Of Pretax Income
Net Earnings	-$23.74M	-$33.06M	-$95.90M
YoY Change	4.42%	49.06%	-438.67%
Net Earnings / Revenue	-2228.92%	-2691.86%	-1540.56%
Basic Earnings Per Share	-$0.10		-$0.39
Diluted Earnings Per Share	-$0.10	-$0.13	-$0.39
COMMON SHARES
Basic Shares Outstanding	248.9M shares	248.9M shares	244.5M shares
Diluted Shares Outstanding	249.2M shares		244.5M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.76M	$62.86M	$62.86M
YoY Change	-57.0%	12.34%	12.34%
Cash & Equivalents	$17.48M	$7.578M	$7.578M
Short-Term Investments	$27.28M	$55.28M	$55.28M
Other Short-Term Assets	$3.626M	$4.325M	$4.325M
YoY Change	-80.0%	-91.01%	-91.01%
Inventory
Prepaid Expenses
Receivables	$872.0K	$902.0K	$902.0K
Other Receivables	$290.0K	$673.0K	$673.0K
Total Short-Term Assets	$49.55M	$68.76M	$68.76M
YoY Change	-64.03%	-41.81%	-41.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.62M	$7.111M	$14.21M
YoY Change	82.69%	-2.97%	-7.83%
Goodwill	$26.56M	$26.61M
YoY Change	-28.16%	-27.93%
Intangibles	$38.72M	$40.70M
YoY Change	-11.7%	-8.44%
Long-Term Investments
YoY Change
Other Assets	$751.0K	$767.0K	$767.0K
YoY Change	-25.2%	-25.17%	-25.17%
Total Long-Term Assets	$85.30M	$82.29M	$82.29M
YoY Change	-17.82%	-15.88%	-15.88%
TOTAL ASSETS
Total Short-Term Assets	$49.55M	$68.76M	$68.76M
Total Long-Term Assets	$85.30M	$82.29M	$82.29M
Total Assets	$134.8M	$151.0M	$151.0M
YoY Change	-44.17%	-30.07%	-30.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.716M	$1.726M	$1.726M
YoY Change	23.81%	-57.57%	-57.57%
Accrued Expenses	$23.65M	$20.75M	$20.75M
YoY Change	-18.7%	-33.78%	-33.78%
Deferred Revenue	$407.0K	$509.0K
YoY Change	2613.33%	1936.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$28.77M	$22.99M	$22.99M
YoY Change	-38.43%	-70.77%	-70.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.275M	$7.713M	$7.713M
YoY Change	-13.81%	-12.45%	-12.45%
Total Long-Term Liabilities	$7.275M	$7.713M	$7.713M
YoY Change	-13.81%		-12.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$28.77M	$22.99M	$22.99M
Total Long-Term Liabilities	$7.275M	$7.713M	$7.713M
Total Liabilities	$37.83M	$32.55M	$32.55M
YoY Change	-34.11%	-63.73%	-63.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.988B	-$1.965B
YoY Change	5.12%	5.13%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$97.02M	$118.5M	$118.5M
YoY Change
Total Liabilities & Shareholders Equity	$134.8M	$151.0M	$151.0M
YoY Change	-44.17%	-30.07%	-30.07%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$23.74M	-$33.06M	-$95.90M
YoY Change	4.42%	49.06%	-438.67%
Depreciation, Depletion And Amortization	$1.595M	$1.618M	$6.668M
YoY Change	-6.78%	-5.98%	-38.06%
Cash From Operating Activities	-$14.09M	-$15.77M	-$66.90M
YoY Change	-23.37%	2.43%	2.85%
INVESTING ACTIVITIES
Capital Expenditures	$4.351M	$1.046M	$1.536M
YoY Change	2725.32%	1873.58%	-68.81%
Acquisitions
YoY Change
Other Investing Activities	$28.40M	$14.34M	-$1.551M
YoY Change	-156.5%	24.97%	-100.67%
Cash From Investing Activities	$24.05M	$13.29M	-$3.087M
YoY Change	-147.7%	16.39%	-101.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$0.00		$43.22M
YoY Change	-100.0%		-72.06%
Cash From Financing Activities	$0.00	-1.000K	$29.59M
YoY Change	-100.0%	-100.0%	-119.05%
NET CHANGE
Cash From Operating Activities	-$14.09M	-15.77M	-$66.90M
Cash From Investing Activities	$24.05M	13.29M	-$3.087M
Cash From Financing Activities	$0.00	-1.000K	$29.59M
Net Change In Cash	$9.895M	-2.478M	-$40.75M
YoY Change	-140.14%	-94.27%	-875.71%
FREE CASH FLOW
Cash From Operating Activities	-$14.09M	-$15.77M	-$66.90M
Capital Expenditures	$4.351M	$1.046M	$1.536M
Free Cash Flow	-$18.44M	-$16.82M	-$68.44M
YoY Change	-0.54%	8.85%	-2.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	594000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48596000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001356090
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member
CY2023	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetImpairmentCharges
CY2022	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetImpairmentCharges
CY2021	us-gaap	Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetImpairmentCharges
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36042
CY2023	dei	Entity Registrant Name EntityRegistrantName	PRECIGEN, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	VA
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-0084895
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	20374 Seneca Meadows Parkway
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Germantown,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20876
CY2023	dei	City Area Code CityAreaCode	301
CY2023	dei	Local Phone Number LocalPhoneNumber	556-9900
CY2023	dei	Security12b Title Security12bTitle	Common Stock, No Par Value
CY2023	dei	Trading Symbol TradingSymbol	PGEN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	177300000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	248919096	shares
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7578000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4858000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	43339000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	55277000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	51092000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	184000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	902000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	978000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	673000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	12826000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4325000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5066000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	68755000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	118159000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7111000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	215977000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	108094000	usd
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	18641000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7329000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	40701000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	44455000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	26612000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	36923000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7097000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8086000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	767000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1025000	usd
CY2023Q4	us-gaap	Assets Assets	151043000	usd
CY2022Q4	us-gaap	Assets Assets	215977000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1726000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4068000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8250000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6377000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6223000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4997000	usd
CY2023Q4	pgen	Settlement And Indemnification Accruals Current SettlementAndIndemnificationAccrualsCurrent	5075000	usd
CY2022Q4	pgen	Settlement And Indemnification Accruals Current SettlementAndIndemnificationAccrualsCurrent	18750000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	509000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	43219000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1202000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1209000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22985000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	78645000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1818000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1818000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5895000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6992000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1847000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2263000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	32545000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	89718000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	256398527	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	208150021	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	248919096	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	208150021	shares
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2084916000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1998314000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1964471000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1868567000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1947000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3488000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	118498000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126259000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151043000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-95904000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	28317000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-92166000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.39
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.39
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.40
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.40
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.56
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.56
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.54
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.54
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.09
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.09
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	244536221	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	244536221	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	200360821	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	200360821	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	197759900	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	197759900	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-95904000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	28317000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-92166000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	727000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-431000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-344000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	814000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3262000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3450000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94363000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	24624000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-95960000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	67174000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13904000	usd
CY2021	pgen	Stock Issued During Period Value Restricted Stock Awards Vestedand Stock Optionsand Warrants Exercised StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsandWarrantsExercised	608000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	577000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	121045000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-92166000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3794000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	107348000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	107348000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10207000	usd
CY2022	pgen	Stock Issued During Period Value Restricted Stock Awards Vested And Stock Options Exercised StockIssuedDuringPeriodValueRestrictedStockAwardsVestedAndStockOptionsExercised	1000	usd
CY2022	pgen	Stock Issued During The Period Value Accrued Compensation StockIssuedDuringThePeriodValueAccruedCompensation	1698000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	575000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	28317000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3691000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126259000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126259000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9888000	usd
CY2023	pgen	Stock Issued During The Period Value Accrued Compensation StockIssuedDuringThePeriodValueAccruedCompensation	3361000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	545000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	72808000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-95904000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1541000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	118498000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-95904000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	28317000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-92166000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6668000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10765000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13761000	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	72000	usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-421000	usd
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-150000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10390000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	482000	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	445000	usd
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	638000	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	543000	usd
CY2023	pgen	Disposal Group Including Discontinued Operation Gain Losson Disposal DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal	0	usd
CY2022	pgen	Disposal Group Including Discontinued Operation Gain Losson Disposal DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal	94702000	usd
CY2021	pgen	Disposal Group Including Discontinued Operation Gain Losson Disposal DisposalGroupIncludingDiscontinuedOperationGainLossonDisposal	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	60000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	961000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1809000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-832000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1232000	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	862000	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9888000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	10206000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	13904000	usd
CY2023	pgen	Shares Issued During Period Value Issued For Services Expense SharesIssuedDuringPeriodValueIssuedForServicesExpense	545000	usd
CY2022	pgen	Shares Issued During Period Value Issued For Services Expense SharesIssuedDuringPeriodValueIssuedForServicesExpense	575000	usd
CY2021	pgen	Shares Issued During Period Value Issued For Services Expense SharesIssuedDuringPeriodValueIssuedForServicesExpense	577000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	944000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1268000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	60000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1042000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-479000	usd
CY2023	pgen	Noncash Gain Loss On Termination Of Lease NoncashGainLossOnTerminationOfLease	0	usd
CY2022	pgen	Noncash Gain Loss On Termination Of Lease NoncashGainLossOnTerminationOfLease	0	usd
CY2021	pgen	Noncash Gain Loss On Termination Of Lease NoncashGainLossOnTerminationOfLease	5831000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-107000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-24000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-76000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2175000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6230000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-12153000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	11338000	usd
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	330000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-748000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2630000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1383000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-129000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	101000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-305000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2421000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	379000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	420000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	5227000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-37000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2853000	usd
CY2023	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	782000	usd
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1517000	usd
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1858000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	484000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-23396000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1656000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-107000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-107000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	97000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-37000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-50000	usd
CY2023	pgen	Increase Decrease Settlement And Identification Accruals IncreaseDecreaseSettlementAndIdentificationAccruals	-13675000	usd
CY2022	pgen	Increase Decrease Settlement And Identification Accruals IncreaseDecreaseSettlementAndIdentificationAccruals	13000000	usd
CY2021	pgen	Increase Decrease Settlement And Identification Accruals IncreaseDecreaseSettlementAndIdentificationAccruals	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66930000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65045000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55771000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	185026000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	174221000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	183377000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	68441000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	100168000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1536000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4924000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7247000	usd
CY2023	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	98000	usd
CY2021	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	3006000	usd
CY2023	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
CY2022	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	162306000	usd
CY2021	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
CY2023	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	usd
CY2021	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	3754000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3087000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	226417000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74540000	usd
CY2023	pgen	Proceedsfrom Issuanceof Common Stockand Warrants Net ProceedsfromIssuanceofCommonStockandWarrantsNet	72808000	usd
CY2022	pgen	Proceedsfrom Issuanceof Common Stockand Warrants Net ProceedsfromIssuanceofCommonStockandWarrantsNet	0	usd
CY2021	pgen	Proceedsfrom Issuanceof Common Stockand Warrants Net ProceedsfromIssuanceofCommonStockandWarrantsNet	121045000	usd
CY2023	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	120000	usd
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	588000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	43219000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	155293000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	466000	usd
CY2023	pgen	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	0	usd
CY2022	pgen	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	1000	usd
CY2021	pgen	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	608000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29589000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-155292000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	121187000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-320000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-827000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	217000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40748000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5253000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8907000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43343000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52250000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7848000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48596000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43343000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1171000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	8535000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7155000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	21000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	36000	usd
CY2023	pgen	Accrued Compensation Paidin Equity Awards AccruedCompensationPaidinEquityAwards	3361000	usd
CY2022	pgen	Accrued Compensation Paidin Equity Awards AccruedCompensationPaidinEquityAwards	1698000	usd
CY2021	pgen	Accrued Compensation Paidin Equity Awards AccruedCompensationPaidinEquityAwards	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	566000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	40000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	820000	usd
CY2023	pgen	Sale Of Assets Included In Receivables SaleOfAssetsIncludedInReceivables	0	usd
CY2022	pgen	Sale Of Assets Included In Receivables SaleOfAssetsIncludedInReceivables	0	usd
CY2021	pgen	Sale Of Assets Included In Receivables SaleOfAssetsIncludedInReceivables	14000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7578000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4858000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	43339000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	270000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	399000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7848000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48596000	usd
CY2023Q4	pgen	Number Of Wholly Owned Operating Subsidiaries NumberOfWhollyOwnedOperatingSubsidiaries	2	subsidiary
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-95900000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66900000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1964500000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	62900000	usd
CY2023	pgen	Collaboration Agreement Termination Notice Period CollaborationAgreementTerminationNoticePeriod	P90D
CY2023Q4	pgen	Research And Development Commitments Not Yet Incurred ResearchAndDevelopmentCommitmentsNotYetIncurred	17800000	usd
CY2022Q4	pgen	Research And Development Commitments Not Yet Incurred ResearchAndDevelopmentCommitmentsNotYetIncurred	19909000	usd
CY2023	pgen	Highly Liquid Investment Maximum Maturity Period HighlyLiquidInvestmentMaximumMaturityPeriod	P3M
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	43339000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company's fixed rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2023, gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions. Although the Company has no intent to liquidate such investments, depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade and other receivables. The Company manages credit risk through credit approvals, credit limits, and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.</span></div>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23018874	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15899091	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12850556	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div>
CY2022Q3	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	162306000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2327000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1843000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	509000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1818000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1818000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2327000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1843000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	55310000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	103000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	136000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	55277000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	51852000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	760000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	51092000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	55277000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	55277000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	51092000	usd
CY2023Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	164000	usd
CY2022Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	164000	usd
CY2023Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	2629000	usd
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	2592000	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	530000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	457000	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	18576000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	18006000	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	4380000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	4333000	usd
CY2023Q4	pgen	Breedingand Production Animals Gross BreedingandProductionAnimalsGross	79000	usd
CY2022Q4	pgen	Breedingand Production Animals Gross BreedingandProductionAnimalsGross	123000	usd
CY2023Q4	pgen	Computer Hardwareand Software ComputerHardwareandSoftware	3459000	usd
CY2022Q4	pgen	Computer Hardwareand Software ComputerHardwareandSoftware	4562000	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	1577000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	531000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31394000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30768000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24283000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	23439000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7111000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7329000	usd
CY2023	us-gaap	Depreciation Depreciation	1820000	usd
CY2022	us-gaap	Depreciation Depreciation	2393000	usd
CY2021	us-gaap	Depreciation Depreciation	2866000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	445000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	638000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	543000	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	24873000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	14483000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4848000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4798000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5273000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4770000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4770000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4770000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4770000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4134000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	17487000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40701000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	43219000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	200000000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	759000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96362000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79966000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110967000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-247000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	37000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	37000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-39000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	7000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-152000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-198000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-215000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	21000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-80000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	11000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-458000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-189000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-160000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20236000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-16793000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23303000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-6693000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3417000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	179000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	832000	usd
CY2023	pgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation	278000	usd
CY2022	pgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation	263000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2884000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4670000	usd
CY2021	pgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation	1459000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	101000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	0	usd
CY2023	pgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Equity Investment Loss EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityInvestmentLoss	0	usd
CY2022	pgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Equity Investment Loss EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityInvestmentLoss	3093000	usd
CY2021	pgen	Effective Income Tax Rate Reconciliation Nondeductible Expense Equity Investment Loss EffectiveIncomeTaxRateReconciliationNondeductibleExpenseEquityInvestmentLoss	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1383000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	991000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	958000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-15000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	18000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-32000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1109000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	533000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-46000	usd
CY2023	pgen	Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance	-23523000	usd
CY2022	pgen	Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance	-16481000	usd
CY2021	pgen	Income Tax Reconciliation Income Tax Expense Benefit Before Valuation Allowance IncomeTaxReconciliationIncomeTaxExpenseBenefitBeforeValuationAllowance	-26718000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	23065000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16292000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	26558000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-458000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-189000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-160000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	48000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	53000	usd
CY2023Q4	pgen	Deferred Tax Asset Equity Method Investmentsand Investments Accounted For Under The Fair Value Option DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption	413000	usd
CY2022Q4	pgen	Deferred Tax Asset Equity Method Investmentsand Investments Accounted For Under The Fair Value Option DeferredTaxAssetEquityMethodInvestmentsandInvestmentsAccountedForUnderTheFairValueOption	258000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	369000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	284000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	64013000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	69807000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3262000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3219000	usd
CY2023Q4	pgen	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	1834000	usd
CY2022Q4	pgen	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	2182000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	14465000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	17106000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	478000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	474000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	23918000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	16318000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13577000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	12160000	usd
CY2023Q4	pgen	Deferred Tax Assets Operating Capital Loss And Interest Expense Carryforwards DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards	311154000	usd
CY2022Q4	pgen	Deferred Tax Assets Operating Capital Loss And Interest Expense Carryforwards DeferredTaxAssetsOperatingCapitalLossAndInterestExpenseCarryforwards	288397000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	433531000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	410258000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	424432000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	401086000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9099000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9172000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	52000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	170000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	252000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	384000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	422000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1830000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2071000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	9116000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	9364000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10946000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11435000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1847000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2263000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	401086000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	408396000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	387348000	usd
CY2023	pgen	Valuation Allowance Deferred Tax Asset Change In Amount Current Year Operations ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations	23065000	usd
CY2022	pgen	Valuation Allowance Deferred Tax Asset Change In Amount Current Year Operations ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations	16292000	usd
CY2021	pgen	Valuation Allowance Deferred Tax Asset Change In Amount Current Year Operations ValuationAllowanceDeferredTaxAssetChangeInAmountCurrentYearOperations	26558000	usd
CY2023	pgen	Valuation Allowance Deferred Tax Assets Discontinued Operations Treated As Asset Sales ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales	0	usd
CY2022	pgen	Valuation Allowance Deferred Tax Assets Discontinued Operations Treated As Asset Sales ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales	-27909000	usd
CY2021	pgen	Valuation Allowance Deferred Tax Assets Discontinued Operations Treated As Asset Sales ValuationAllowanceDeferredTaxAssetsDiscontinuedOperationsTreatedAsAssetSales	-3626000	usd
CY2023	pgen	Valuation Allowance Deferred Tax Assets Discontinued Operations ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations	0	usd
CY2022	pgen	Valuation Allowance Deferred Tax Assets Discontinued Operations ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations	0	usd
CY2021	pgen	Valuation Allowance Deferred Tax Assets Discontinued Operations ValuationAllowanceDeferredTaxAssetsDiscontinuedOperations	-1186000	usd
CY2023	pgen	Valuation Allowance Deferred Tax Asset Change In Foreign Currency Translation Adjustment ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment	281000	usd
CY2022	pgen	Valuation Allowance Deferred Tax Asset Change In Foreign Currency Translation Adjustment ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment	-391000	usd
CY2021	pgen	Valuation Allowance Deferred Tax Asset Change In Foreign Currency Translation Adjustment ValuationAllowanceDeferredTaxAssetChangeInForeignCurrencyTranslationAdjustment	-698000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	424432000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	401086000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	408396000	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	43962640	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	43962640	shares
CY2021Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	17250000	shares
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	121045000	usd
CY2018Q3	us-gaap	Ownshare Lending Arrangement Shares Issued OwnshareLendingArrangementSharesIssued	7479431	shares
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	800000	usd
CY2023	us-gaap	Lease Cost LeaseCost	2670000	usd
CY2022	us-gaap	Lease Cost LeaseCost	3036000	usd
CY2021	us-gaap	Lease Cost LeaseCost	3924000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9888000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10206000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13904000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	ten
CY2023	pgen	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P1Y
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2234000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2444000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2872000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1946000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1911000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1507000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1239000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1260000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1847000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9710000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2613000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7097000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1202000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5895000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	7097000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y4M20D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M2D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1120
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1105
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2326000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2493000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3199000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	399000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	466000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4868000	usd
CY2023	pgen	Net Income Loss Attributableto Parent Adjusted Ebitda Including Cash Paidfor Capital Expendituresand Investmentsin Affiliates NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates	-76065000	usd
CY2022	pgen	Net Income Loss Attributableto Parent Adjusted Ebitda Including Cash Paidfor Capital Expendituresand Investmentsin Affiliates NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates	-72545000	usd
CY2021	pgen	Net Income Loss Attributableto Parent Adjusted Ebitda Including Cash Paidfor Capital Expendituresand Investmentsin Affiliates NetIncomeLossAttributabletoParentAdjustedEBITDAIncludingCashPaidforCapitalExpendituresandInvestmentsinAffiliates	-71993000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-96362000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79966000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110967000	usd
CY2023	pgen	Number Of Customers NumberOfCustomers	4	customer
CY2021	pgen	Number Of Customers NumberOfCustomers	1	customer
CY2022	pgen	Number Of Customers NumberOfCustomers	1	customer
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	482000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-149000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	36923000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	79000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	10390000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	26612000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	178000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	564000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	388000	usd

Files In Submission

Name	View Source	Status
0001356090-24-000007-index-headers.html	Edgar Link	pending
0001356090-24-000007-index.html	Edgar Link	pending
0001356090-24-000007.txt	Edgar Link	pending
0001356090-24-000007-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pgen-20231231.htm	Edgar Link	pending
pgen-20231231.xsd	Edgar Link	pending
pgen-20231231xexx1010.htm	Edgar Link	pending
pgen-20231231xexx1010001.jpg	Edgar Link	pending
pgen-20231231xexx1010002.jpg	Edgar Link	pending
pgen-20231231xexx1010003.jpg	Edgar Link	pending
pgen-20231231xexx1010004.jpg	Edgar Link	pending
pgen-20231231xexx1011.htm	Edgar Link	pending
pgen-20231231xexx1011001.jpg	Edgar Link	pending
pgen-20231231xexx1011002.jpg	Edgar Link	pending
pgen-20231231xexx1011003.jpg	Edgar Link	pending
pgen-20231231xexx1011004.jpg	Edgar Link	pending
pgen-20231231xexx1011005.jpg	Edgar Link	pending
pgen-20231231xexx1011006.jpg	Edgar Link	pending
pgen-20231231xexx109.htm	Edgar Link	pending
pgen-20231231xexx109001.jpg	Edgar Link	pending
pgen-20231231xexx109002.jpg	Edgar Link	pending
pgen-20231231xexx109003.jpg	Edgar Link	pending
pgen-20231231xexx211.htm	Edgar Link	pending
pgen-20231231xexx231.htm	Edgar Link	pending
pgen-20231231xexx311.htm	Edgar Link	pending
pgen-20231231xexx312.htm	Edgar Link	pending
pgen-20231231xexx321.htm	Edgar Link	pending
pgen-20231231xexx322.htm	Edgar Link	pending
pgen-20231231xexx97.htm	Edgar Link	pending
pgen-20231231xexx97001.jpg	Edgar Link	pending
pgen-20231231xexx97002.jpg	Edgar Link	pending
pgen-20231231xexx97003.jpg	Edgar Link	pending
pgen-20231231xexx97004.jpg	Edgar Link	pending
pgen-20231231xexx97005.jpg	Edgar Link	pending
pgen-20231231_g1.jpg	Edgar Link	pending
pgen-20231231_g10.jpg	Edgar Link	pending
pgen-20231231_g11.jpg	Edgar Link	pending
pgen-20231231_g12.jpg	Edgar Link	pending
pgen-20231231_g13.jpg	Edgar Link	pending
pgen-20231231_g14.jpg	Edgar Link	pending
pgen-20231231_g15.jpg	Edgar Link	pending
pgen-20231231_g16.jpg	Edgar Link	pending
pgen-20231231_g17.jpg	Edgar Link	pending
pgen-20231231_g18.jpg	Edgar Link	pending
pgen-20231231_g19.jpg	Edgar Link	pending
pgen-20231231_g2.jpg	Edgar Link	pending
pgen-20231231_g20.jpg	Edgar Link	pending
pgen-20231231_g21.jpg	Edgar Link	pending
pgen-20231231_g22.jpg	Edgar Link	pending
pgen-20231231_g23.jpg	Edgar Link	pending
pgen-20231231_g24.jpg	Edgar Link	pending
pgen-20231231_g25.jpg	Edgar Link	pending
pgen-20231231_g26.jpg	Edgar Link	pending
pgen-20231231_g27.jpg	Edgar Link	pending
pgen-20231231_g28.jpg	Edgar Link	pending
pgen-20231231_g3.jpg	Edgar Link	pending
pgen-20231231_g4.jpg	Edgar Link	pending
pgen-20231231_g5.jpg	Edgar Link	pending
pgen-20231231_g6.jpg	Edgar Link	pending
pgen-20231231_g7.jpg	Edgar Link	pending
pgen-20231231_g8.jpg	Edgar Link	pending
pgen-20231231_g9.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
pgen-20231231_def.xml	Edgar Link	unprocessable
pgen-20231231_lab.xml	Edgar Link	unprocessable
pgen-20231231_pre.xml	Edgar Link	unprocessable
pgen-20231231_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pgen-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PGEN
PRECIGEN, INC. Stock $pgen

2024 Q1 Form 10-K Financial Statement

#000135609024000007 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PGEN PRECIGEN, INC. Stock $pgen

2024 Q1 Form 10-K Financial Statement

#000135609024000007 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PGEN
PRECIGEN, INC. Stock $pgen